AstraZeneca Plc

AstraZeneca results and presentations

Material Q3 growth moderation, but profitability improvement continued

Compared with H1 20, AstraZeneca witnessed a pertinent slowdown in Q3 sales growth. Growth was again driven by Oncology and aptly supported by the New CVRM, while R&I was weak. However, the recovery in profitability was sustained – especially on the back of sales & marketing activities of the earlie ...

SP Angel Healthcare Conditions- 12-10-2020

EVENT: Yellowstone Advisory Webinar with Simon Young

Unearthing winners, avoiding losers and learning from mistakes

An assessment of Astra’s COVID-19 vaccine journey

AstraZeneca (an inexperienced vaccine player) has emerged as top contender in the COVID-19 vaccine race, post its deal with Oxford University. The potential vaccine’s much-lower price and multiple out-licensing deals, resulting in major capacities being secured, have been two critical miles ...

Growth continued in Q2, profitability better but more to be achieved

AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a front-runner in the COVID-19 vaccine race. While there were some profitability improvements as wel ...